Literature DB >> 32054650

Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls.

Sæmundur Rögnvaldsson1, Vilhjálmur Steingrímsson2, Ingemar Turesson3, Magnus Björkholm4, Ola Landgren5, Sigurður Yngvi Kristinsson2.   

Abstract

Keywords:  Clinical and Molecular Epidemiology; Monoclonal Gammopathy of Undetermined Significance; Neuropathy; Population-based; Quality of Life

Year:  2020        PMID： 32054650      PMCID： PMC7604635          DOI： 10.3324/haematol.2019.239632

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study.

Authors:  Elsa S Strotmeyer; Jane A Cauley; Ann V Schwartz; Michael C Nevitt; Helaine E Resnick; Douglas C Bauer; Frances A Tylavsky; Nathalie de Rekeneire; Tamara B Harris; Anne B Newman
Journal:  Arch Intern Med       Date:  2005-07-25

3.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

4.  Diabetic peripheral neuropathy and quality of life.

Authors:  S J Benbow; M E Wallymahmed; I A MacFarlane
Journal:  QJM       Date:  1998-11

5.  Neuropathy associated with monoclonal gammopathies of undetermined significance.

Authors:  S Gosselin; R A Kyle; P J Dyck
Journal:  Ann Neurol       Date:  1991-07       Impact factor: 10.422

6.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

7.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

8.  Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

Authors:  Normann Steiner; Angelika Schwärzler; Georg Göbel; Wolfgang Löscher; Julia Wanschitz; Eberhard Gunsilius
Journal:  Oncotarget       Date:  2017-01-17

9.  The Impact of Diabetic Neuropathy on Balance and on the Risk of Falls in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Authors:  Bogdan Timar; Romulus Timar; Laura Gaiță; Cristian Oancea; Codrina Levai; Diana Lungeanu
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

Review 10.  The epidemiology and risk factors of chronic polyneuropathy.

Authors:  Rens Hanewinckel; Marieke van Oijen; M Arfan Ikram; Pieter A van Doorn
Journal:  Eur J Epidemiol       Date:  2015-12-23       Impact factor: 8.082
View more
  1 in total

Review 1.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.